Wexford Capital’s Standard BioTools LAB Stock Holding History

Wexford Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-83,638	Closed	-$100K	–	433
2025 Q2	$100K	Hold	83,638	–	–	0.03%	208
2025 Q1	$90.3K	Hold	83,638	–	–	0.02%	203
2024 Q4	$146K	Hold	83,638	–	–	0.02%	174
2024 Q3	$161K	Sell	83,638 -23,981	-22%	-$47K	0.04%	158
2024 Q2	$190K	Buy	+107,619	New	+$263K	0.05%	177

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Wexford Capital's LAB Position: Q3 2025 in Review

Wexford Capital sold out of Standard BioTools (LAB) in Q3 2025, closing a stake of 83,638 shares — an estimated $100K sold.

Wexford Capital first reported a position in LAB in Q2 2024 and held it in 5 quarters. The position peaked at $190K in Q2 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q3 2025.

Wexford Capital reported no remaining Standard BioTools position as of Q3 2025 after selling out during the quarter.
Wexford Capital sold 83,638 Standard BioTools shares in Q3 2025, an estimated $100K.
Wexford Capital first reported a position in Standard BioTools in Q2 2024 and held it in 5 quarters.
Wexford Capital's Standard BioTools position peaked at $190K in Q2 2024.
155 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2025.

Based on Wexford Capital's 13F filing for Q3 2025, filed 14 Nov 2025.